The PD-1- and LAG-3-targeting bispecific molecule tebotelimab in solid tumors and hematologic cancers: a phase 1 trialJason J. Luke, Paul A. Moore, Bartosz Chmielowski et al.|Nature Medicine|2023Cited by 135
A Phase 1, Open-Label Study of MGD013, a Bispecific DART® Molecule Binding PD-1 and LAG-3 in Patients with Relapsed or Refractory Diffuse Large B-Cell LymphomaJie Wang, Bradley Sumrow, Adam S. Asch et al.|Blood|2020Cited by 25